🚀 VC round data is live in beta, check it out!
Bora Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bora Pharmaceuticals and similar public comparables like RAPT Therapeutics, Chongqing Genrix, Hanall Biopharma, Star Lake Bioscience and more.
Bora Pharmaceuticals Overview
About Bora Pharmaceuticals
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Commercial sales segment, Contract Development & Manufacturing Organization segment, and Other segment. The majority of revenue is derived from the Commercial sales segment. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
Founded
2007
HQ
Employees
163
Website
Financials (LTM)
EV
$2B
Bora Pharmaceuticals Financials
Bora Pharmaceuticals reported last 12-month revenue of $633M and EBITDA of $223M.
In the same LTM period, Bora Pharmaceuticals generated $279M in gross profit, $223M in EBITDA, and $106M in net income.
Revenue (LTM)
Bora Pharmaceuticals P&L
In the most recent fiscal year, Bora Pharmaceuticals reported revenue of $603M and EBITDA of $218M.
Bora Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $633M | XXX | $603M | XXX | XXX | XXX |
| Gross Profit | $279M | XXX | $249M | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $223M | XXX | $218M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 36% | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $106M | XXX | $94M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | — | — | $392M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bora Pharmaceuticals Stock Performance
Bora Pharmaceuticals has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Bora Pharmaceuticals' stock price is $13.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -2.1% | XXX | XXX | XXX | $0.74 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBora Pharmaceuticals Valuation Multiples
Bora Pharmaceuticals trades at 3.3x EV/Revenue multiple, and 9.4x EV/EBITDA.
EV / Revenue (LTM)
Bora Pharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Bora Pharmaceuticals has market cap of $2B and EV of $2B.
Equity research analysts estimate Bora Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bora Pharmaceuticals has a P/E ratio of 15.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 9.4x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 17.6x | XXX | 20.0x | XXX | XXX | XXX |
| EV/Gross Profit | 7.5x | XXX | 8.4x | XXX | XXX | XXX |
| P/E | 15.8x | XXX | 17.8x | XXX | XXX | XXX |
| EV/FCF | (13.5x) | XXX | 18.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bora Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bora Pharmaceuticals Margins & Growth Rates
Bora Pharmaceuticals' revenue in the last 12 month grew by 21%.
Bora Pharmaceuticals' revenue per employee in the last FY averaged $3.7M, while opex per employee averaged $0.9M for the same period.
Bora Pharmaceuticals' rule of 40 is 51% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bora Pharmaceuticals' rule of X is 78% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Bora Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 51% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 78% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $3.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bora Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bora Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| RAPT Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Chongqing Genrix | XXX | XXX | XXX | XXX | XXX | XXX |
| Hanall Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Star Lake Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Yantai Dongcheng | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bora Pharmaceuticals M&A Activity
Bora Pharmaceuticals acquired XXX companies to date.
Last acquisition by Bora Pharmaceuticals was on XXXXXXXX, XXXXX. Bora Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bora Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBora Pharmaceuticals Investment Activity
Bora Pharmaceuticals invested in XXX companies to date.
Bora Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Bora Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bora Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bora Pharmaceuticals
| When was Bora Pharmaceuticals founded? | Bora Pharmaceuticals was founded in 2007. |
| Where is Bora Pharmaceuticals headquartered? | Bora Pharmaceuticals is headquartered in Taiwan. |
| How many employees does Bora Pharmaceuticals have? | As of today, Bora Pharmaceuticals has over 163 employees. |
| Is Bora Pharmaceuticals publicly listed? | Yes, Bora Pharmaceuticals is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of Bora Pharmaceuticals? | Bora Pharmaceuticals trades under 6472 ticker. |
| When did Bora Pharmaceuticals go public? | Bora Pharmaceuticals went public in 2014. |
| Who are competitors of Bora Pharmaceuticals? | Bora Pharmaceuticals main competitors are RAPT Therapeutics, Chongqing Genrix, Hanall Biopharma, Star Lake Bioscience. |
| What is the current market cap of Bora Pharmaceuticals? | Bora Pharmaceuticals' current market cap is $2B. |
| What is the current revenue of Bora Pharmaceuticals? | Bora Pharmaceuticals' last 12 months revenue is $633M. |
| What is the current revenue growth of Bora Pharmaceuticals? | Bora Pharmaceuticals revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Bora Pharmaceuticals? | Current revenue multiple of Bora Pharmaceuticals is 3.3x. |
| Is Bora Pharmaceuticals profitable? | Yes, Bora Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bora Pharmaceuticals? | Bora Pharmaceuticals' last 12 months EBITDA is $223M. |
| What is Bora Pharmaceuticals' EBITDA margin? | Bora Pharmaceuticals' last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Bora Pharmaceuticals? | Current EBITDA multiple of Bora Pharmaceuticals is 9.4x. |
| What is the current FCF of Bora Pharmaceuticals? | Bora Pharmaceuticals' last 12 months FCF is ($155M). |
| What is Bora Pharmaceuticals' FCF margin? | Bora Pharmaceuticals' last 12 months FCF margin is (24%). |
| What is the current EV/FCF multiple of Bora Pharmaceuticals? | Current FCF multiple of Bora Pharmaceuticals is (13.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.